pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial
Boehringer Ingelheim
Boehringer Ingelheim clinical programs — 94 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
- Employees
- 46,699
- Programs
- 193
- Drugs
- 113
- Patents
- 25
Boehringer Ingelheim projects
94 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.
Boehringer Ingelheim has 94 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
1479-0015
Boehringer Ingelheim
Pharmacokinetic trial
1 trial -
1479-0019
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1479-0047
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1480-0001
Boehringer Ingelheim
Advanced solid tumours
1 trial -
1485-0013
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1490-0006
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1493-0008
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1501-0002
Boehringer Ingelheim
Head and neck squamous cell carcinoma
1 trial -
1505-0001
Boehringer Ingelheim
Metastatic pancreatic ductal adenocarcinoma (mPDAC)
1 trial -
1507-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1509-0002
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1509-0003
Boehringer Ingelheim
Type 1 interferonopathies
1 trial -
1509-0007
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1509-0010
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1509-0014
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1516-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1516-0002
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1516-0003
Boehringer Ingelheim
Attention deficit hyperactivity disorder, Borderline personality disorder
1 trial -
1516-0004
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1519-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1519-0002
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1519-0004
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1524-0001
Boehringer Ingelheim
Metabolic Dysfunction-associated Steatohepatitis
1 trial -
1526-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1527-0001
Boehringer Ingelheim
Melanoma, Solid tumours
1 trial -
1530-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1530-0002
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1533-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
1538-0001
Boehringer Ingelheim
advanced, unresectable and/or metastatic solid tumors
1 trial -
1543-0001
Boehringer Ingelheim
healthy volunteer trial
1 trial -
2001-0001
Boehringer Ingelheim
Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours
1 trial -
2007-0001
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
2012-0001
Boehringer Ingelheim
unresectable advanced or metastatic solid cancer
1 trial -
A study in healthy men to test how BI 1569912 is processed in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy men to test how BI 1584862 is processed in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to compare two different Sifrol® tablets
Boehringer Ingelheim
Pharmacokinetic trial
1 trial -
A study in healthy people to compare two tablet formulations of pramipexole
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how vicadrostat affects the heart
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
BI 1015550, NERANDOMILAST
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
BI 3011441
Boehringer Ingelheim
Solid Tumors, KRAS Mutation
1 trial -
BI 695502
Boehringer Ingelheim
Healthy
1 trial -
BI 765063
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
BI 905711
Boehringer Ingelheim
Gastrointestinal Neoplasms
1 trial -
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
Boehringer Ingelheim
G12D/G12V Pancreatic Ductal Adenocarcinoma
1 trial -
Lendormin tablet
Boehringer Ingelheim
Healthy
1 trial -
Spesolimab
Boehringer Ingelheim
Psoriasis
1 trial
Frequently asked questions
How many clinical projects does Boehringer Ingelheim have?
94 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.